Prelude Therapeutics Incorporated (PRLD) has a consensus analyst rating of Buy, based on 8 analysts covering the stock. Of those, 5 recommend buying, 1 recommend holding, and 2 recommend selling.
The analyst consensus price target for PRLD is $6.25, representing a +42.0% upside from the current price of $4.4. Price targets range from a low of $3.00 to a high of $10.00.
